Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 13/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.53 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711792 | 0.89 | STAT3 (0.67) | STAT3CA1CA2LTB4R2 | |
| Meglumine SCHEMBL2853649 | 0.85 | STAT3 (0.45) | STAT3PTPN11PTPROHNF4ALTB4R2 | |
| SCHEMBL2855309 | 0.84 | CNR2 (0.55) | STAT3PTPN11PTPRO | |
| SCHEMBL2857060 | 0.84 | STAT3 (0.57) | STAT3PTPN11PTPROHNF4ALTB4R2 | |
| SCHEMBL2856083 | 0.84 | STAT3 (0.71) | STAT3PTPN11PTPROPDK2PDK4 | |
| SCHEMBL2855206 | 0.82 | STAT3 (0.54) | STAT3PTPN11PTPROHNF4ACA1 | |
| SCHEMBL2853410 | 0.82 | STAT3 (0.60) | STAT3PTPN11PTPROHNF4APDK2 | |
| SCHEMBL2853433 | 0.81 | STAT3 (0.75) | STAT3PTPN11PTPROPDK2PDK4 | |
| SCHEMBL2852841 | 0.81 | STAT3 (0.52) | STAT3PTPN11PTPROHNF4AMEN1 | |
| SCHEMBL2851611 | 0.81 | STAT3 (0.49) | STAT3PTPN11PTPROLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | claimed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | claimed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | claimed |
| EP-1654247-B1 | ALKYNYL ARYL CARBOXAMIDES | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-7589232-B2 | Alkynyl aryl carboxamides | LABORATORIES SERONO S.A. (CH) | 2009-09-15 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| US-20070105913-A1 | Alkynyl aryl carboxamides | APPLIED RESEARCH SYSTEMS ARS HOLDINGS N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| EP-1654247-A1 | ALKYNYL ARYL CARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012280-A1 | ALKYNYL ARYL CARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105913-A1 | Alkynyl aryl carboxamides | ECHS1, IRS1, HCCS | STAT3 2684/4885PTPN11 97/4885PTPRO 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.